1型糖尿病幼儿使用混合闭环系统18个月:单臂多中心试验
在一项针对1-7岁1型糖尿病幼儿的16周多国随机交叉试验(混合闭环 vs 传感器增强泵)后,49名参与者进入延长阶段继续使用混合闭环系统18个月。与 primary-phase SAP 期相比,延长阶段TIR高8.4个百分点(95%CI 6.7-10.1;P<0.001),HbA1c低0.4%([5.0 mmol/mol],95%CI 0.3-0.6 [3.7-6.2];P<0.001);18个月时HbA1c 6.7±0.5%、TIR 70±7%,与 primary-phase CL 期的6.7±0.5%和71±6%相近。低血糖时间在延长阶段与SAP期(P=0.31)及CL期(P=0.70)均相似。
要点
- 与 primary-phase SAP 期相比,延长阶段TIR高8.4个百分点(95%CI 6.7-10.1;P<0.001)。
- 与 primary-phase SAP 期相比,延长阶段HbA1c低0.4%([5.0 mmol/mol],95%CI 0.3-0.6 [3.7-6.2];P<0.001)。
- 延长阶段低血糖时间与SAP期(P=0.31)及CL期(P=0.70)均相似。
核心结论
- 在1型糖尿病幼儿中使用Cambridge混合闭环系统可使血糖控制改善持续超过18个月。
研究设计与样本
- 在74名1-7岁1型糖尿病幼儿中完成16周多国随机交叉试验(混合闭环 vs 传感器增强泵)后,邀请参与者进入延长阶段继续使用混合闭环系统18个月。
- 延长阶段共49名参与者同意继续使用混合闭环系统18个月,平均±SD年龄6.6±1.5岁。
- 结局与 primary-phase SAP 期及 primary-phase CL 期进行比较。
主要发现
- 与 primary-phase SAP 期相比,延长阶段TIR(3.9-10.0 mmol/L)高8.4个百分点(95%CI 6.7-10.1;P<0.001)。
- 与 primary-phase SAP 期相比,延长阶段HbA1c低0.4%([5.0 mmol/mol],95%CI 0.3-0.6 [3.7-6.2];P<0.001)。
- 18个月时平均HbA1c为6.7±0.5%、TIR为70±7%,而 primary-phase CL 期为6.7±0.5%和71±6%。
- 延长阶段低血糖(<3.9 mmol/L)时间与 primary-phase SAP 期(P=0.31)及 primary-phase CL 期(P=0.70)均相似。
- 延长阶段发生2例严重低血糖事件和1例其他严重不良事件;发生1例意外严重器械不良效应。
临床怎么用
- 作者认为,使用Cambridge混合闭环系统可使1型糖尿病幼儿的血糖控制改善持续超过18个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to evaluate the longer-term safety and efficacy of hybrid closed-loop (CL) therapy in very young children with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Following a 16-week multinational, randomized crossover trial comparing hybrid CL with sensor-augmented pump (SAP) therapy in 74 very young children aged 1-7 years with T1D, participants were invited to an extension phase using CL for a further 18 months. Outcomes were compared with the primary-phase SAP period and primary-phase CL period. RESULTS: After the primary study phase, 60 participants were eligible to enroll in the extension. Of these, 49 consented (mean ± SD age 6.6 ± 1.5 years) to continue use of CL for 18 months. Percentage time in range (TIR) 3.9-10.0 mmol/L was 8.4 percentage points (95% CI 6.7-10.1; P < 0.001) higher, while HbA1c was 0.4% ([5.0 mmol/mol], 95% CI 0.3-0.6 [3.7-6.2]; P < 0.001) lower during the CL extension phase compared with primary-phase SAP period. At 18 months, mean HbA1c was 6.7 ± 0.5% and TIR was 70 ± 7%, compared with 6.7 ± 0.5% and 71 ± 6% in the primary-phase CL period. Time in hypoglycemia (<3.9 mmol/L) was similar between CL extension phase and both primary-phase SAP (P = 0.31) and CL periods (P = 0.70). There were two severe hypoglycemia events and one other serious adverse event during the extension phase. One unexpected serious adverse device effect occurred. CONCLUSIONS: Use of the Cambridge hybrid CL system led to sustained improvements in glycemic control lasting more than 18 months in very young children with T1D.
引用
- Ware J, Allen JM, Boughton CK, et al. Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial. Diabetes Care. 2024. PMID: 39418532. doi:10.2337/dc24-1313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。